DnB Asset Management AS Has $17.76 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

DnB Asset Management AS raised its position in Hologic, Inc. (NASDAQ:HOLX) by 16.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 246,285 shares of the medical equipment provider’s stock after buying an additional 35,662 shares during the period. DnB Asset Management AS’s holdings in Hologic were worth $17,755,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. denkapparat Operations GmbH acquired a new stake in Hologic during the 4th quarter worth approximately $426,000. Nomura Asset Management Co. Ltd. grew its stake in shares of Hologic by 1.5% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 121,417 shares of the medical equipment provider’s stock worth $8,753,000 after purchasing an additional 1,771 shares during the last quarter. Triodos Investment Management BV increased its holdings in Hologic by 19.1% in the fourth quarter. Triodos Investment Management BV now owns 42,000 shares of the medical equipment provider’s stock valued at $3,028,000 after purchasing an additional 6,750 shares during the period. Norges Bank bought a new position in Hologic during the 4th quarter worth $133,414,000. Finally, Caisse Des Depots ET Consignations acquired a new position in Hologic during the 4th quarter worth about $1,473,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Down 1.6 %

Hologic stock opened at $61.32 on Friday. The firm has a market capitalization of $13.76 billion, a price-to-earnings ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 1-year low of $60.34 and a 1-year high of $84.67. The firm’s fifty day moving average price is $65.24 and its two-hundred day moving average price is $73.35.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on HOLX shares. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a research report on Monday, February 3rd. Morgan Stanley reduced their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Royal Bank of Canada lowered their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.